101 reports of this reaction
1.5% of all OMEPRAZOLE AND SODIUM BICARBONATE reports
#13 most reported adverse reaction
TUBULOINTERSTITIAL NEPHRITIS is the #13 most commonly reported adverse reaction for OMEPRAZOLE AND SODIUM BICARBONATE, manufactured by Santarus, Inc... There are 101 FDA adverse event reports linking OMEPRAZOLE AND SODIUM BICARBONATE to TUBULOINTERSTITIAL NEPHRITIS. This represents approximately 1.5% of all 6,647 adverse event reports for this drug.
Patients taking OMEPRAZOLE AND SODIUM BICARBONATE who experience tubulointerstitial nephritis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TUBULOINTERSTITIAL NEPHRITIS is a less commonly reported adverse event for OMEPRAZOLE AND SODIUM BICARBONATE, but still significant enough to appear in the safety profile.
In addition to tubulointerstitial nephritis, the following adverse reactions have been reported for OMEPRAZOLE AND SODIUM BICARBONATE:
The following drugs have also been linked to tubulointerstitial nephritis in FDA adverse event reports:
TUBULOINTERSTITIAL NEPHRITIS has been reported as an adverse event in 101 FDA reports for OMEPRAZOLE AND SODIUM BICARBONATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
TUBULOINTERSTITIAL NEPHRITIS accounts for approximately 1.5% of all adverse event reports for OMEPRAZOLE AND SODIUM BICARBONATE, making it a notable side effect.
If you experience tubulointerstitial nephritis while taking OMEPRAZOLE AND SODIUM BICARBONATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.